Erlotinib
Title: Erlotinib
CAS Registry Number: 183321-74-6
CAS Name: N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine
Molecular Formula: C22H23N3O4
Molecular Weight: 393.44
Percent Composition: C 67.16%, H 5.89%, N 10.68%, O 16.27%
Literature References: Selective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor. Prepn: R. C. Schnur, L. D. Arnold, WO 9630347; eidem, US 5747498 (1996, 1998 both to Pfizer). Mechanism of action study: J. D. Moyer et al., Cancer Res. 57, 4838 (1997). Enzyme inhibition and antitumor activity: V. A. Pollack et al., J. Pharmacol. Exp. Ther. 291, 739 (1999). HPLC determn in plasma: E. R. Lepper et al., J. Chromatogr. B 796, 181 (2003). Clinical pharmacokinetics: M. Hidalgo et al., J. Clin. Oncol. 19, 3267 (2001). Clinical evaluation in non-small-cell lung cancer: R. Pérez-Soler et al., J. Clin. Oncol. 22, 3238 (2004). Review of pharmacology and clinical development: T. E. Kim, J. R. Murren, Curr. Opin. Invest. Drugs 3, 1385-1395 (2002); and use in non-small cell lung cancer: F. H. Blackhall et al., Expert Opin. Pharmacother. 6, 995-1002 (2005).
 
Derivative Type: Hydrochloride
CAS Registry Number: 183319-69-9
Manufacturers' Codes: CP-358774; OSI-774
Trademarks: Tarceva (OSI)
Molecular Formula: C22H23N3O4.HCl
Molecular Weight: 429.90
Percent Composition: C 61.46%, H 5.63%, N 9.77%, O 14.89%, Cl 8.25%
Properties: mp 228-230°. pKa (25°): 5.42. Soly in water (pH ~2): ~0.4 mg/ml. Slightly sol in methanol. Practically insol in acetonitrile, acetone, ethyl acetate, hexane.
Melting point: mp 228-230°
pKa: pKa (25°): 5.42
 
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Tyrosine Kinase Inhibitors.

Others monographs:
CobaltAltheaBrodifacoumSarafloxacin
N4-SulfanilylsulfanilamideFerrous ChlorideMPTPCupric Oxalate
RifamycinsNeoergosterolPteroic AcidMethdilazine
AzelastineGlybuzoleEvening Primrose OilAmicibone
©2016 DrugLead US FDA&EMEA